Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
ROIV Forecast Markets
Roivant Sciences Ltd.
7
Active Markets
46%
Avg Probability
All Markets
7 markets
Will the FDA approve brepocitinib for dermatomyositis by 2026-09-30?
79%
Likely Yes
95% agreement
Sep 30, 2026
IG: 0.80
Will brepocitinib's non-infectious uveitis Phase 3 topline be positive by 2027-03-31?
50%
Likely No
96% agreement
Mar 31, 2027
IG: 0.64
Will IMVT-1402 difficult-to-treat RA Ph2b topline be positive by 2027-03-31?
48%
Likely No
93% agreement
Mar 31, 2027
IG: 0.64
Will IMVT-1402 cutaneous lupus Ph2 PoC readout be positive by 2027-03-31?
50%
Likely No
96% agreement
Mar 31, 2027
IG: 0.56
Will mosliciguat Ph2 PH-ILD topline be positive by 2027-03-31?
45%
Likely No
94% agreement
Mar 31, 2027
IG: 0.56
Will the FDA convene an Advisory Committee for brepocitinib DM by 2026-09-15?
25%
Likely No
93% agreement
Sep 15, 2026
IG: 0.48
Will ROIV announce an M&A deal deploying over $500M by 2026-12-31?
25%
Likely No
94% agreement
Dec 31, 2026
IG: 0.48
Resolution Timeline
Sep 15, 2026
Will the FDA convene an Advisory Committee for brepocitinib DM by 2026-09-15?Prediction: 25%
Mar 31, 2027
Will brepocitinib's non-infectious uveitis Phase 3 topline be positive by 2027-03-31?Prediction: 50%
Mar 31, 2027
Will IMVT-1402 difficult-to-treat RA Ph2b topline be positive by 2027-03-31?Prediction: 48%
Mar 31, 2027
Will IMVT-1402 cutaneous lupus Ph2 PoC readout be positive by 2027-03-31?Prediction: 50%